← 產業報告目錄

Artificial Intelligence in Diabetes Management Market Research Report by Type (Diagnostics, Treatment Planning, Data Management, Patient Self-Management), by Deployment (Cloud-Based, On-Premises, Hybrid), by Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), by end-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diabetes Treatment Centers, Patients), and by Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) Forecast till 2035

出版商 Market Research Future產業別 Healthcare & Life Sciences出版日期 2026-02-22頁數 183報告編號 MRFRHC25230CR

授權報價

Single User Price$4,950 USD
Multi User Licence (up to 10 users)$5,950 USD
Enterprisewide Price (Global Site License)$7,250 USD
洽詢購買 申請 Sample

報告摘要

Valued at USD 1,568.64 million in 2024, the Global Artificial Intelligence in Diabetes Management Market is anticipated to expand significantly, reaching USD 14,239.56 million by 2035. This growth reflects a strong CAGR of 22.76% over the 2025–2035 period, fueled by advancements in AI-based diagnostics and monitoring tools. Expansion of Connected Diabetes Devices The rapid adoption of connected devices such as CGMs, smart insulin pens, and AI-enabled wearables is a primary driver of the Global Artificial Intelligence in Diabetes Management Market, enabling real-time monitoring and personalized treatment. These technologies significantly improve glycemic control, treatment adherence, and proactive prevention of complications. Concise Segment Insights By Type • Diagnostics: AI enables faster, accurate diabetes detection • Treatment Planning: Personalized AI-driven insulin and therapy optimization • Data Management: Efficient handling of large patient datasets • Patient Self-Management: AI tools support daily glucose monitoring By Deployment • Cloud-Based: Scalable platforms enable real-time data access • On-Premises: Ensures data security and local system control • Hybrid: Combines flexibility with enhanced data protection By Application • Type 1 Diabetes: Continuous monitoring and insulin dose precision • Type 2 Diabetes: Lifestyle tracking with AI-based intervention insights • Gestational Diabetes: Temporary monitoring ensuring maternal-fetal health By End-User • Hospitals and Clinics: Advanced AI tools improve clinical decision-making • Ambulatory Surgical Centers: Efficient monitoring during outpatient procedures • Diabetes Treatment Centers: Specialized care with AI-driven analytics • Patients: Self-care tools enhance engagement and adherence Regional Market Snapshot North America dominates with over 40% share driven by advanced infrastructure, while Europe follows with strong regulatory-backed adoption and healthcare integration. Asia Pacific shows the fastest expansion due to high prevalence and digital growth, while South America and MEA emerge steadily with cost-effective, mobile-first AI solutions. Strategic AI Collaboration Initiative In May 2024, Sanofi partnered with Formation Bio and OpenAI to develop AI-powered solutions aimed at accelerating drug discovery and development. This collaboration integrates proprietary data, advanced software, and tailored AI models to enhance efficiency across the pharmaceutical lifecycle. AI-Driven Personalization Advantage The integration of generative AI and predictive analytics provides a strategic edge by enabling highly personalized diabetes management through synthetic data generation and advanced modeling. These technologies enhance clinical decision-making, improve treatment precision, and support proactive intervention strategies. Key Report Attributes • Market Size 2024: USD 1568.64 Million • Market Size 2035: USD 14239.56 Million • CAGR (2025-2035): 22.76% • Base Year: 2024 • Market Forecast Period: 2025-2035 Industry Segmentations Growth • By Type: Diagnostics - 23.03%, Treatment Planning - 22.27%. • By Deployment: Cloud-Based - 23.68%, On-Premises - 22.21%. • By Application: Type 1 Diabetes - 25.39%, Type 2 Diabetes - 22.43%. • By end-User: Hospitals and Clinics - 22.05%, Ambulatory Surgical Centers - 22.34%.
目錄 Table of Contents
TABLE OF CONTENTS 1 EXECUTIVE SUMMARY ...... 20 2 MARKET INTRODUCTION ...... 22 2.1 DEFINITION ...... 22 2.2 SCOPE OF THE STUDY ....... 22 2.3 RESEARCH OBJECTIVE ........ 22 2.4 MARKET STRUCTURE ....... 23 3 RESEARCH METHODOLOGY ...... 24 3.1 OVERVIEW ........ 24 3.2 DATA FLOW ...... 26 3.2.1 DATA MINING PROCESS ...... 26 3.3 PURCHASED DATABASE: ........ 27 3.4 SECONDARY SOURCES: ........ 28 3.4.1 SECONDARY RESEARCH DATA FLOW: ....... 29 3.5 PRIMARY RESEARCH: ........ 30 3.5.1 PRIMARY RESEARCH DATA FLOW: ........ 31 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ....... 32 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ........ 32 3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ....... 33 3.6.1 REVENUE ANALYSIS APPROACH ...... 33 3.7 DATA FORECASTING....... 34 3.7.1 DATA FORECASTING TYPE ...... 34 3.8 DATA MODELING ........ 35 3.8.1 MICROECONOMIC FACTOR ANALYSIS: ...... 35 3.8.2 DATA MODELING: ....... 36 3.9 TEAMS AND ANALYST CONTRIBUTION ........ 38 4 MARKET DYNAMICS ........ 40 4.1 INTRODUCTION ........ 40 4.2 DRIVERS ....... 41 4.2.1 RISING GLOBAL DIABETES PREVALENCE ...... 41 4.2.2 ADVANCEMENTS IN CONNECTED DEVICES AND DIGITAL HEALTH INFRASTRUCTURE ...... 42 4.2.3 SHIFT TOWARD PERSONALIZED AND PREDICTIVE HEALTHCARE....... 42 4.2.4 INCREASED ADOPTION OF CLOUD AND SAAS HEALTHCARE PLATFORMS ........ 42 4.3 RESTRAINTS ....... 44 4.3.1 HIGH IMPLEMENTATION AND INTEGRATION COSTS ....... 44 4.3.2 DATA PRIVACY AND CYBERSECURITY CONCERNS ....... 44 4.3.3 LIMITED INTEROPERABILITY ACROSS DEVICES AND EHR SYSTEMS ........ 44 4.4 OPPORTUNITIES ...... 45 4.4.1 EXPANSION OF REMOTE PATIENT MONITORING (RPM) AND TELEHEALTH ....... 45 4.4.2 EMERGENCE OF GENERATIVE AI AND PREDICTIVE ANALYTICS ...... 46 4.4.3 PARTNERSHIPS BETWEEN TECH GIANTS AND HEALTHCARE PROVIDERS ...... 47 5 MARKET FACTOR ANALYSIS ...... 48 5.1 VALUE CHAIN ANALYSIS ...... 48 5.1.1 DATA GENERATION & ACQUISITION ....... 48 5.1.2 DATA PROCESSING & STORAGE ....... 48 5.1.3 AI MODEL DEVELOPMENT ...... 48 5.1.4 INTEGRATION WITH DEVICES & PLATFORMS ...... 49 5.1.5 CLINICAL VALIDATION & REGULATORY APPROVAL ...... 49 5.1.6 DEPLOYMENT & COMMERCIALIZATION ........ 49 5.1.7 PATIENT ENGAGEMENT & FEEDBACK ....... 49 5.1.8 CONTINUOUS LEARNING & MODEL OPTIMIZATION ...... 49 5.2 PORTER'S FIVE FORCES MODEL ...... 50 5.2.1 THREAT OF NEW ENTRANTS ...... 51 5.2.2 BARGAINING POWER OF SUPPLIERS ...... 51 5.2.3 THREAT OF SUBSTITUTES ...... 51 5.2.4 BARGAINING POWER OF BUYERS ........ 51 5.2.5 INTENSITY OF RIVALRY ....... 51 5.3 COVID-19 IMPACT ANALYSIS ........ 51 6 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE ........ 54 6.1 OVERVIEW ........ 54 6.1.1 DIAGNOSTICS ...... 56 6.1.2 TREATMENT PLANNING ...... 57 6.1.3 DATA MANAGEMENT ....... 57 6.1.4 PATIENT SELF MANAGEMENT ...... 58 7 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT….. 59 7.1 OVERVIEW ........ 59 7.1.1 CLOUD-BASED ...... 61 7.1.2 ON-PREMISES ...... 61 7.1.3 HYBRID ....... 62 8 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION ….. 63 8.1 OVERVIEW ........ 63 8.1.1 TYPE 1 DIABETES ....... 65 8.1.2 TYPE 2 DIABETES ....... 65 8.1.3 GESTATIONAL DIABETES ........ 66 9 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER ….. 67 9.1 OVERVIEW ........ 67 9.1.1 HOSPITALS AND CLINICS ....... 69 9.1.2 AMBULATORY SURGICAL CENTERS ........ 70 9.1.3 DIABETES TREATMENT CENTERS........ 70 9.1.4 PATIENTS ...... 71 10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION ... 72 10.1 OVERVIEW ........ 72 10.2 NORTH AMERICA ....... 73 10.2.1 US...... 76 10.2.2 CANADA ........ 78 10.3 EUROPE ........ 81 10.3.1 GERMANY ...... 84 10.3.2 FRANCE ...... 86 10.3.3 UK ........ 88 10.3.4 SPAIN ...... 90 10.3.5 ITALY ....... 92 10.3.6 RUSSIA ....... 94 10.3.7 REST OF EUROPE ........ 96 10.4 ASIA-PACIFIC ...... 98 10.4.1 CHINA ...... 101 10.4.2 INDIA ....... 103 10.4.3 JAPAN ........ 105 10.4.4 SOUTH KOREA ...... 107 10.4.5 MALAYSIA ........ 109 10.4.6 THAILAND ...... 110 10.4.7 INDONESIA ........ 112 10.4.8 REST OF ASIA-PACIFIC ........ 114 10.5 SOUTH AMERICA ....... 116 10.5.1 BRAZIL ........ 119 10.5.2 MEXICO ...... 121 10.5.3 ARGENTINA ...... 123 10.5.4 REST OF SOUTH AMERICA ...... 125 10.6 MIDDLE EAST & AFRICA ...... 127 10.6.1 GCC COUNTRIES...... 131 10.6.2 SOUTH AFRICA ........ 133 10.6.3 REST OF MEA ....... 135 11 COMPETITIVE LANDSCAPE ........ 138 11.1 INTRODUCTION ........ 138 11.2 MARKET SHARE ANALYSIS, 2024 ........ 138 11.3 COMPETITOR DASHBOARD....... 139 11.4 PUBLIC PLAYERS STOCK SUMMARY ........ 140 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ...... 140 11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES ........ 141 11.1.1 PRODUCT LAUNCH ........ 141 11.1.2 PARTNERSHIP ...... 141 11.1.3 ACQUISITION/ EXPANSION ........ 141 11.1.4 AI-ENABLED ...... 142 12 COMPANY PROFILES ...... 143 12.1 ELI LILLY AND COMPANY ...... 143 12.1.1 COMPANY OVERVIEW ....... 143 12.1.2 FINANCIAL OVERVIEW ...... 145 12.1.3 PRODUCTS/ SERVICE OFFERED ........ 146 12.1.4 KEY DEVELOPMENTS ........ 146 12.1.5 SWOT ANALYSIS ........ 147 12.1.6 KEY STRATEGIES ........ 147 12.2 ASTRAZENECA...... 148 12.2.1 COMPANY OVERVIEW ....... 148 12.2.2 FINANCIAL OVERVIEW ...... 149 12.2.3 PRODUCTS OFFERED ........ 150 12.2.4 KEY DEVELOPMENTS ........ 150 12.2.5 SWOT ANALYSIS ........ 151 12.2.6 KEY STRATEGIES ........ 151 12.3 SANOFI ...... 152 12.3.1 COMPANY OVERVIEW ....... 152 12.3.2 FINANCIAL OVERVIEW ...... 153 12.3.3 PRODUCTS OFFERED ........ 154 12.3.4 KEY DEVELOPMENTS ........ 154 12.3.5 KEY STRATEGIES ........ 154 12.4 NOVO NORDISK A/S ...... 156 12.4.1 COMPANY OVERVIEW ....... 156 12.4.2 FINANCIAL OVERVIEW ...... 157 12.4.3 PRODUCTS OFFERED ........ 158 12.4.4 KEY DEVELOPMENTS ........ 158 12.4.5 SWOT ANALYSIS ........ 159 12.4.6 KEY STRATEGIES ........ 159 12.5 TANDEM DIABETES CARE, INC. ....... 160 12.5.1 COMPANY OVERVIEW ....... 160 12.5.2 FINANCIAL OVERVIEW ...... 161 12.5.3 PRODUCTS OFFERED ........ 162 12.5.4 KEY DEVELOPMENTS ........ 162 12.5.5 SWOT ANALYSIS ........ 163 12.5.6 KEY STRATEGIES ........ 163 12.6 F. HOFFMANN-LA ROCHE LTD. ........ 164 12.6.1 COMPANY OVERVIEW ....... 164 12.6.2 FINANCIAL OVERVIEW ...... 165 12.6.3 PRODUCTS/SERVICES OFFERED ....... 166 12.6.4 KEY DEVELOPMENTS ........ 166 12.6.5 SWOT ANALYSIS ........ 167 12.6.6 KEY STRATEGIES ........ 167 12.7 ABBOTT ........ 168 12.7.1 COMPANY OVERVIEW ....... 168 12.7.2 FINANCIAL OVERVIEW ...... 169 12.7.3 PRODUCTS/SERVICES OFFERED ....... 169 12.7.4 KEY DEVELOPMENTS ........ 170 12.7.5 KEY STRATEGIES ........ 170 12.8 MEDTRONIC ........ 171 12.8.1 COMPANY OVERVIEW ....... 171 12.8.2 FINANCIAL OVERVIEW ...... 172 12.8.3 PRODUCTS/SERVICES OFFERED ....... 173 12.8.4 KEY DEVELOPMENTS ........ 173 12.8.5 SWOT ANALYSIS ........ 173 12.8.6 KEY STRATEGIES ........ 174 12.9 DEXCOM INC. ...... 175 12.9.1 COMPANY OVERVIEW ....... 175 12.9.2 FINANCIAL OVERVIEW ...... 176 12.9.3 PRODUCTS/SERVICES OFFERED ....... 177 12.9.4 KEY DEVELOPMENTS ........ 177 12.9.5 KEY STRATEGIES ........ 177 12.10 INSULET CORPORATION ...... 178 12.10.1 COMPANY OVERVIEW ....... 178 12.10.2 FINANCIAL OVERVIEW ...... 179 12.10.3 PRODUCTS/SERVICES OFFERED ....... 179 12.10.4 KEY DEVELOPMENTS ........ 180 12.10.5 SWOT ANALYSIS ........ 180 12.10.6 KEY STRATEGY ........ 181 13 DATA CITATIONS ....... 182
圖表清單 List of Tables & Figures
LIST OF TABLES TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 37 TABLE 2 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 55 TABLE 3 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR DIAGNOSTICS, BY REGION, 2019–2035 (USD MILLION) 56 TABLE 4 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR TREATMENT PLANNING, BY REGION, 2019–2035 (USD MILLION) 57 TABLE 5 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR DATA MANAGEMENT, BY REGION, 2019–2035 (USD MILLION) 57 TABLE 6 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR PATIENT SELF MANAGEMENT, BY REGION, 2019 2035 (USD MILLION) 58 TABLE 7 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 60 TABLE 8 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR CLOUD-BASED, BY REGION, 2019–2035 (USD MILLION) 61 TABLE 9 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR ON-PREMISES, BY REGION, 2019–2035 (USD MILLION) 61 TABLE 10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR HYBRID, BY REGION, 2019–2035 (USD MILLION) 62 TABLE 11 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 64 TABLE 12 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR TYPE 1 DIABETES, BY REGION, 2019–2035 (USD MILLION) 65 TABLE 13 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR TYPE 2 DIABETES, BY REGION, 2019–2035 (USD MILLION) 65 TABLE 14 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR GESTATIONAL DIABETES, BY REGION, 2019–2035 (USD MILLION) 66 TABLE 15 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 68 TABLE 16 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR HOSPITALS AND CLINICS, BY REGION, 2019–2035 (USD MILLION) 69 TABLE 17 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2019–2035 (USD MILLION) 70 TABLE 18 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR DIABETES TREATMENT CENTERS, BY REGION, 2019-2035 (USD MILLION) 70 TABLE 19 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, FOR PATIENTS, BY REGION, 2019–2035 (USD MILLION) TABLE 20 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION, 2019-2035 (USD MILLION) 72 TABLE 21 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 74 TABLE 22 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 75 TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) TABLE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 25 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 76 TABLE 26 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 76 TABLE 27 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 77 TABLE 28 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 77 TABLE 29 US: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 78 TABLE 30 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 78 TABLE 31 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 79 TABLE 32 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 79 TABLE 33 CANADA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 80 TABLE 34 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 82 TABLE 35 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 83 TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 83 TABLE 37 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 83 TABLE 38 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 84 TABLE 39 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 84 TABLE 40 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 85 TABLE 41 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 85 TABLE 42 GERMANY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 85 TABLE 43 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 86 TABLE 44 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 86 TABLE 45 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 87 TABLE 46 FRANCE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 87 TABLE 47 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 88 TABLE 48 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 88 TABLE 49 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 89 TABLE 50 UK: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 89 TABLE 51 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 90 TABLE 52 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 90 TABLE 53 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 91 TABLE 54 SPAIN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 91 TABLE 55 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 92 TABLE 56 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 92 TABLE 57 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 93 TABLE 58 ITALY: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 93 TABLE 59 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 94 TABLE 60 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 94 TABLE 61 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 95 TABLE 62 RUSSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 95 TABLE 63 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 96 TABLE 64 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) TABLE 65 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) TABLE 66 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 97 TABLE 67 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019–2035 (USD MILLION) 99 TABLE 68 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 100 TABLE 69 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 100 TABLE 70 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 100 TABLE 71 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 101 TABLE 72 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 101 TABLE 73 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 102 TABLE 74 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 102 TABLE 75 CHINA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 102 TABLE 76 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 103 TABLE 77 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 103 TABLE 78 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 104 TABLE 79 INDIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 104 TABLE 80 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 105 TABLE 81 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 105 TABLE 82 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 106 TABLE 83 JAPAN: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 106 TABLE 84 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 107 TABLE 85 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 107 TABLE 86 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 108 TABLE 87 SOUTH KOREA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 108 TABLE 88 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 109 TABLE 89 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 109 TABLE 90 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 109 TABLE 91 MALAYSIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 110 TABLE 92 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 110 TABLE 93 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 111 TABLE 94 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 111 TABLE 95 THAILAND: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 111 TABLE 96 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 112 TABLE 97 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 112 TABLE 98 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 113 TABLE 99 INDONESIA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) 113 TABLE 100 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2019–2035 (USD MILLION) 114 TABLE 101 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019–2035 (USD MILLION) 114 TABLE 102 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019–2035 (USD MILLION) 115 TABLE 103 REST OF ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019–2035 (USD MILLION) TABLE 104 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 117 TABLE 105 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) 118 TABLE 106 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) TABLE 107 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) TABLE 108 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) 119 TABLE 109 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) TABLE 110 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 120 TABLE 111 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 120 TABLE 112 BRAZIL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) 120 TABLE 113 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) 121 TABLE 114 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 121 TABLE 115 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) TABLE 116 MEXICO ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) TABLE 117 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) TABLE 118 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) TABLE 119 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) TABLE 120 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) TABLE 121 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) TABLE 122 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) TABLE 123 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) TABLE 124 ARGENTINA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) TABLE 125 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION)128 TABLE 126 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) TABLE 127 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) TABLE 128 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) TABLE 129 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) TABLE 130 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) TABLE 131 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) TABLE 132 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION)132 TABLE 133 GCC COUNTRIES ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) 132 TABLE 134 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) TABLE 135 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 133 TABLE 136 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 134 TABLE 137 SOUTH AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) TABLE 138 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MARKET, BY TYPE, 2019-2035 (USD MILLION) TABLE 139 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2019-2035 (USD MILLION) 135 TABLE 140 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2019-2035 (USD MILLION) 136 TABLE 141 REST OF MEA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2019-2035 (USD MILLION) TABLE 142 PRODUCT LAUNCH TABLE 143 PARTNERSHIP TABLE 144 ACQUISITION/ EXPANSION TABLE 145 AI-ENABLED TABLE 146 ELI LILLY AND COMPANY: PRODUCTS OFFERED TABLE 147 ASTRAZENECA: PRODUCTS OFFERED TABLE 148 SANOFI: PRODUCTS OFFERED TABLE 149 SANOFI: KEY DEVELOPMENTS TABLE 150 NOVO NORDISK A/S: PRODUCTS OFFERED TABLE 151 TANDEM DIABETES CARE, INC.: PRODUCTS OFFERED TABLE 152 TANDEM DIABETES CARE, INC.: KEY DEVELOPMENTS TABLE 153 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED TABLE 154 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED TABLE 155 ABBOTT.: PRODUCTS/SERVICES OFFERED TABLE 156 MEDTRONIC: PRODUCTS/SERVICES OFFERED TABLE 157 MEDTRONIC: KEY DEVELOPMENTS TABLE 158 DEXCOM, INC: PRODUCTS/SERVICES OFFERED TABLE 159 INSULET CORPORATION.: PRODUCTS/SERVICES OFFERED TABLE 160 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED LIST OF FIGURES FIGURE 1 GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DIABETES MANAGEMENT MARKET: STRUCTURE 23 FIGURE 1 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET: MARKET GROWTH AFFECTING FACTOR ANALYSIS (2019-2035) 40 FIGURE 2 SHARE OF PEOPLE WITH DIABETES, 2024 41 FIGURE 3 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET DRIVER: IMPACT ANALYSIS 43 FIGURE 4 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET RESTRAINT: IMPACT ANALYSIS 45 FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DIABETES MANAGEMENT MARKET 50 FIGURE 6 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, TYPE SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 54 FIGURE 7 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY TYPE, 2024 & 2035 (USD MILLION) 55 FIGURE 8 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY TYPE, 2024 56 FIGURE 9 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, DEPLOYMENT SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 59 FIGURE 10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY DEPLOYMENT, 2024 & 2035 (USD MILLION) 59 FIGURE 11 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY DEPLOYMENT, 2024 60 FIGURE 12 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 63 FIGURE 13 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY APPLICATION, 2024 & 2035 (USD MILLION) 63 FIGURE 14 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY APPLICATION, 2024 64 FIGURE 15 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, END USER SEGMENT ATTRACTIVENESS, 2024 & 2035 (USD MILLION) 67 FIGURE 16 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY END USER, 2024 & 2035 (USD MILLION) 68 FIGURE 17 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY END USER, 2024 69 FIGURE 18 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY REGION, 2024 & 2035 (USD MILLION) 72 FIGURE 19 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY REGION, 2024 73 FIGURE 20 NORTH AMERICA MARKET ANALYSIS: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, 2019-2035 (USD MILLION) FIGURE 21 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 74 FIGURE 22 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 74 FIGURE 23 EUROPE MARKET ANALYSIS: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, 2019-2035 (USD MILLION) 81 FIGURE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, BY COUNTRY, 2024 & 2035 (USD MILLION) 81 FIGURE 25 EUROPE: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 82 FIGURE 1 ASIA-PACIFIC MARKET ANALYSIS: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET, 2019-2035 (USD MILLION) 98 FIGURE 2 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD MILLION) FIGURE 3 ASIA-PACIFIC: ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE, BY COUNTRY, 2024 (%) 99 FIGURE 4 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET: SWOT ANALYSIS 116 FIGURE 5 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET (, BY COUNTRY, 2024 & 2035 (USD MILLION) 116 FIGURE 6 SOUTH AMERICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 117 FIGURE 7 MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET: SWOT ANALYSIS 127 FIGURE 8 MIDDLE EAST AND AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET (, BY COUNTRY, 2024 & 2035 (USD MILLION) 127 FIGURE 9 MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET SHARE (%), BY COUNTRY, 2024 128 FIGURE 10 GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2024 FIGURE 11 COMPETITOR DASHBOARD: GLOBAL ARTIFICIAL INTELLIGENCE IN DIABETES MANAGEMENT MARKET FIGURE 12 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT FIGURE 13 ELI LILLY AND COMPANY: SWOT ANALYSIS FIGURE 14 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT FIGURE 15 ASTRAZENECA: SWOT ANALYSIS FIGURE 16 SANOFI: FINANCIAL OVERVIEW SNAPSHOT FIGURE 17 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT FIGURE 18 NOVO NORDISK A/S: SWOT ANALYSIS FIGURE 19 TANDEM DIABETES CARE, INC.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 20 TANDEM DIABETES CARE, INC.: SWOT ANALYSIS FIGURE 21 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 22 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS FIGURE 23 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT FIGURE 24 MEDTRONIC: FINANCIAL OVERVIEW SNAPSHOT FIGURE 25 MEDTRONIC: SWOT ANALYSIS FIGURE 26 DEXCOM, INC.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 27 INSULET CORPORATION.: FINANCIAL OVERVIEW SNAPSHOT FIGURE 28 INSULET CORPORATION.: SWOT ANALYSIS

提及公司

Eli Lilly and CompanyAstraZenecaSanofiNovo Nordisk A/STandem Diabetes CareInc. F. Hoffmann-La Roche LtdAbbottMedtronicDexcomInc.Insulet Corporation

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們